63
Views
0
CrossRef citations to date
0
Altmetric
Review

Fentanyl Buccal Tablets for the Treatment of Breakthrough Pain

Pages 533-538 | Published online: 02 Nov 2011

Bibliography

  • Caraceni A , MartiniC, ZeccaE et al. Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat. Med. 18 , 177–183 (2004).
  • Mercadante S , CostanzoBV, FuscoF, ButtàV, VitranoV, CasuccioA. Breakthrough pain in advanced cancer patients followed at home: a longitudinal study. J. Pain Symptom Manage38 , 554–560 (2009).
  • Mercadante S , ZagonelV, BredaE et al. Breakthrough pain in oncology: a longitudinal study. J. Pain Symptom Manage. 40 , 183–190 (2010).
  • Davies AN , DickmanA, ReidC, StevensAM, ZeppetellaG. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur. J. Pain.13 , 331–338 (2009)
  • Portenoy RK , HagenNA. Breakthrough pain: definition, prevalence and characteristics. Pain41 , 273–281 (1990).
  • Mercadante S , RadbruchL, CaraceniA et al. Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care. Cancer 94 , 832–839 (2002).
  • Portenoy RK , PayneD, JacobsenP. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain81 , 129–134 (1999).
  • Zeppetella G . Opioids for cancer breakthrough pain: a pilot study reporting patient assessment of time to meaningful pain relief. J. Pain Symptom Manage.35 , 563–567 (2008).
  • Blick S , WagstaffA. Fentanyl buccal tablet in breakthrough pain in opioid-tolerant patients with cancer. Drugs66 , 2387–2393 (2006).
  • Davies AD , DickmanA, ReidC, StevensA, ZeppetellaG. The management of cancer-related breakthrough pain: recommendations of a task group of the science committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur. J. Pain13 , 331–338 (2009).
  • Darwish M , HamedE, MessinaJ. Fentanyl buccal tablet for the treatment of breakthrough pain: pharmacokinetics of buccal mucosa delivery and clinical efficacy. Perspect. Med. Chem.4 , 11–21 (2010).
  • Grape S , SchugS, LauerS, SchugB. Formulations of fentanyl for the management of pain. Drugs70 , 57–72 (2010).
  • Darwish M , TemperoK, ThompsonJ. Pharmacokinetics and dose proportionality of fentanyl effervescent buccal tablets in healthy volunteers. Clin. Pharmacol.44 , 1279–1286 (2005).
  • Darwish M , KirbyM, RobertsonP, TracewellW, JiangJ. Absolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrate. J. Clin. Pharmacol.47 , 343–350 (2007).
  • Darwish M , KirbyM, JiangJG. Effect of buccal dwell time on the pharmacokinetic profile of fentanyl buccal tablet. Expert Opin. Pharmacother.8 , 2011–2016 (2007).
  • Darwish M , KirbyM, JiangJG, TracewellW, RobertsonP. Bioequivalence following buccal and sublingual placement of fentanyl buccal tablet 400 µg in healthy subjects. Clin. Drug Investig.28 , 1–7 (2008).
  • Messina J , DarwishM, FineP. Fentanyl buccal tablet. Drugs Today44 , 41–54 (2008).
  • Portenoy RK , TaylorD, MessinaJ, TremmelL. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin. J. Pain22 , 805–811 (2006).
  • Slatkin NE , XieF, MessinaJ, SegalTJ. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. J. Support Oncol.5 , 327–334 (2007).
  • Ashburn M , SlevinK, MessinaJ, XieF. The efficacy and safety of fentanyl buccal tablet compared with immediate release oxycodone for the management of breakthrough pain in opioi-tolerant patients with cheonic pain. Anesth. Analg.112 , 693–702 (2011).
  • Portenoy RK , MessinaJ, XieF et al. Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study. Curr. Med. Res. Opin. 23 , 223–233 (2007).
  • Simpson DM , MessinaJ, XieF et al. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients wih chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study. Clin. Ther. 29 , 588–601 (2007).
  • Weinstein SM , MessinaJ, XieF. Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic cancer pain: a long-term, open-label safety study. Cancer115 , 2571–2579 (2009).
  • Farrar J , MessinaJ, XieF, PortenoyRK. A novel 12-week study, with three randomized, double-blind placebo-controlled periods to evaluate fentanyl buccal tablets for the relief of breakthrough pain in opioid-tolerant patients with noncancer-related chronic pain. Pain Med.11 , 1313–1327 (2010).
  • Fine P , MessinaJ, XieF, RathmellJ. Long-term safety and tolerability of fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic pain: an 18-month study. J. Pain Symptom Manage.40 , 747–760 (2010).
  • Nalamachu SR , NarayanaA, JankaL. Long-term dosing, safety, and tolerability of fentanyl buccal tablet in the management of noncancer-related breakthrough pain in opioid-tolerant patients. Curr. Med. Res. Opin.27 , 751–760 (2011).
  • Mercadante S . The use of rapid onset opioids for breakthrough cancer pain: the challenge of its dosing. Crit. Rev. Oncol. Hematol. doi:10.1016/j.critrevonc.2010.12.002 (2011) (Epub ahead of print).
  • Mercadante S , FerreraP, AdileC, CasuccioA. Fentanyl buccal tablets for breakthrough pain in highly tolerant cancer patients: preliminary data on the proportionality between breakthrough pain dose and background dose. J. Pain Symptom Manage.42(3) , 464–469 (2011).
  • Mercadante S , FerreraP, ArcuriE. The use of fentanyl buccal tablets as breakthrough medication in patients receiving chronic methadone therapy: an open label preliminary study. Support Care Cancer19 , 435–438 (2011).
  • Kharasch E , HofferC, WhittingtonD. Influence of age on the pharmacokinetics and pharmacodynamic of oral transmucosal fentanyl citrate. Anesthesiology101 , 738–743 (2004).
  • Nieuw Amerongen AV , VeermanEC. Current therapies for xerostomia and salivary gland hypofunction associated with cancer therapies. Support. Care Cancer11 , 226–231 (2003).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.